3 Dividend Stocks to Buy and Hold for the Next 5 Years

Home Depot investors are facing a tough macro backdrop, with housing starts/completions near multiyear lows and Q2 same-store sales up just 1.7% (1.3% in the U.S.), even as the forward dividend yield sits around 2.8% while a housing cyclical bottom is hoped for. McDonald's reported weaker-than-expected fundamentals—companywide same-store sales +1.3% YoY and U.S. +0.8%—and the stock is down over 20% from its February peak, though management signaled urgency to improve U.S. guest traffic with a ~2.8% forward yield. Johnson & Johnson is the bright spot: it targets growing oncology revenue from ~ $30B annually to at least $50B by 2030 and received FDA clearance for the latest Monarch software, despite only a ~2% forward yield.

Analysis

The more investable signal is not “cautious consumer” or “housing trough,” but where operating leverage is most convex when the cycle turns. In housing, the first money likely goes to the upstream names with the most beta to starts and remodel activity; HD should participate, but it is a slower transmitter of a housing inflection than builders and building-product suppliers. If rates do not ease, the multiple will keep reflecting a late-cycle consumer, so this is a months-not-days setup.

For MCD, the key issue is competitive discipline, not absolute demand. If management restores traffic by leaning harder into value, the upside comes from mix normalization and lower promo intensity versus a broad-based price war; if they need to discount structurally, franchisee economics and royalty growth can both deteriorate, which would pressure the stock’s defensive premium. The biggest second-order winner is whichever QSR chain is perceived as the cleanest value alternative; the loser is likely the entire sector if margin sacrifice becomes necessary.

JNJ is a multi-year rerating story only if oncology can sustain high-single to low-double-digit growth through several reporting cycles; one FDA clearance changes sentiment, not valuation. The market still treats JNJ as a bond proxy, so the upside comes from proving it is a mix-improving compounder, while the risk is pipeline slippage or integration drag from tuck-in deals. Near term, any move is likely capped until investors see a few quarters of cleaner pharma-led acceleration.

Key Decisions for Investors

• Long TOL/BLDR vs short HD on the first confirmed downshift in mortgage rates or a stabilization in housing starts; this is the cleaner housing-beta expression over a 1-3 month horizon. Falsify if rates stay sticky and starts make new lows.
• Stay neutral HD for now; wait for a real inventory/starts inflection before adding. HD is a late-cycle beneficiary, so buying here risks dead money until the housing data actually turns.
• Small tactical long JNJ on pullbacks, preferably via a 12-18 month call spread rather than stock, to express the oncology rerating without paying full dividend-defensive multiple. Exit if pharma growth fails to sustain above peers for two consecutive quarters.
• Do not short MCD outright yet; instead place MCD on a watchlist and look for a re-acceleration in U.S. comp sales without another leg of discounting before getting long. If traffic improves only via heavier promos, the stock can still de-rate despite better top-line reads.
• If you want a QSR relative-value hedge, consider long YUM / short MCD only after seeing whether McDonald's value reset stabilizes traffic. The trade works best if MCD remains inconsistent while Taco Bell keeps taking share among lower-income consumers.